Dementia and Alzheimer's Care Options: Medical Management and Support Services
Alzheimer's disease accounts for 60 to 80 percent of all dementia cases in the United States, according to the Alzheimer's Association, making it the dominant clinical reality behind what families often simply call "memory loss." The care landscape it creates is genuinely complex — spanning medical management, housing decisions, legal planning, and caregiver support across a disease that can unfold over 8 to 20 years. What follows is a structured look at how dementia care actually works: the clinical tools available, the service types that match different stages, and how families can make better decisions at the crossroads moments that dementia reliably produces.
Definition and scope
Dementia is not a single disease but a clinical syndrome — a cluster of symptoms affecting memory, reasoning, communication, and behavior severely enough to interfere with daily function. Alzheimer's is the most common cause, but vascular dementia (caused by reduced blood flow, often following stroke), Lewy body dementia, and frontotemporal dementia each produce distinct symptom profiles with different care implications.
The staging frameworks clinicians use most often are the Global Deterioration Scale (GDS), developed by Dr. Barry Reisberg, and the Clinical Dementia Rating (CDR) scale from Washington University. Both describe a progression from mild cognitive impairment through severe dependence — typically across 7 stages in the GDS model. Stage matters enormously for care planning: a person at GDS Stage 3 can often remain at home with minimal support, while Stage 6 typically requires around-the-clock supervision.
Medical management involves two categories of approved pharmacological intervention. Cholinesterase inhibitors — donepezil, rivastigmine, and galantamine — are FDA-approved for mild to moderate Alzheimer's and work by slowing the breakdown of acetylcholine, a neurotransmitter associated with memory. Memantine (brand name Namenda) targets the glutamate system and is approved for moderate to severe disease. Neither drug reverses progression; both aim to slow functional decline and manage behavioral symptoms. In 2023, the FDA granted full approval to lecanemab (Leqembi), the first amyloid-targeting therapy shown to slow clinical decline in early-stage Alzheimer's, adding a genuinely new tool to a category that had been static for years.
How it works
Dementia care planning functions most effectively when it's built around the disease stage rather than a single care setting. The practical architecture has four pillars:
- Medical management — Primary care or neurology oversight for medications, behavioral symptom control, and monitoring for comorbid conditions that accelerate decline (untreated urinary tract infections, for example, can produce acute confusion in people with dementia that is frequently misread as disease progression).
- Cognitive and functional support — Occupational therapy, structured activity programming, and medication management for seniors that accounts for polypharmacy risks common in this population.
- Supervised care environment — Selected based on the person's current safety risk, mobility, and behavioral profile, ranging from in-home senior care to dedicated memory care services.
- Caregiver and family support — Recognizing that approximately 11 million Americans provide unpaid care for people with Alzheimer's or other dementias (Alzheimer's Association, 2024 Alzheimer's Disease Facts and Figures), caregiver systems are not a secondary concern — they are load-bearing.
Common scenarios
Three situations account for most of the care transitions families navigate:
Early-stage diagnosis at home. Cognitive changes are noticeable but the person retains meaningful independence. In-home support — typically a few hours of companion or personal care daily — preserves autonomy while introducing safety structure. This is also the window for advance directive completion and legal planning. Waiting until moderate-stage dementia to establish durable power of attorney is a documented problem: cognitive capacity requirements mean decisions made too late may not be legally valid.
Moderate-stage with safety concerns. Wandering, medication errors, falls, and night-time behavioral disturbances characterize this transition. Families often reach this stage still providing full care at home, and caregiver burnout signs and solutions become clinically relevant before a placement decision is made. Memory care units — secured residential environments with dementia-specialized programming — are designed specifically for this profile. They differ from standard assisted living in staff training requirements, physical design (circular hallways, secured exits, reduced sensory stimulation), and activity programming ratios.
Late-stage and end-of-life planning. Advanced dementia involves loss of verbal communication, swallowing difficulties, and complete dependence in all ADLs. The evidence base on aggressive intervention — including feeding tubes in late-stage dementia — consistently shows no survival benefit and increased discomfort, per research published in the New England Journal of Medicine. Hospice and palliative care for seniors is appropriate and underutilized at this stage; Medicare hospice eligibility does not require a six-month prognosis certainty, only a physician's clinical judgment that the illness follows a terminal trajectory.
Decision boundaries
The two most consequential forks in dementia care involve setting and financing.
Memory care vs. skilled nursing: Memory care units specialize in behavioral management and structured cognitive engagement but are not equipped for complex medical needs — post-surgical recovery, wound care, IV therapy. When dementia is accompanied by significant physical decline or acute medical events, skilled nursing facility care provides the clinical staffing (registered nurses on-site 24 hours per day under federal regulations at 42 CFR §483.35) that memory care does not. Some continuing care retirement communities house both under one roof, which reduces the trauma of relocation as needs change.
Financing structure: Long-term dementia care is expensive. Genworth's 2023 Cost of Care Survey put the median annual cost of a private-pay memory care unit at approximately $64,200 nationally. Medicare covers acute hospitalization and short-term skilled rehabilitation but does not cover custodial memory care. Medicaid for senior care is the primary payer for long-term dementia care for people who meet income and asset thresholds — a planning reality that benefits from early attention through long-term care insurance or veterans benefits for those who qualify. Understanding how to pay for senior care before a crisis forces the decision is the single most reliable way to preserve options.